Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous

F Schettini, A Mautone, L Cavallo

    Acta Haematologica
    |January 1, 1981
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Standardized handover improves trauma team communication: evidence from a level I Trauma Center in Italy.

    Updates in surgery·2026
    Same author

    Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.

    ESMO real world data and digital oncology·2026
    Same author

    Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

    ESMO open·2026
    Same author

    Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

    ESMO open·2025
    Same author

    Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.

    ESMO open·2025
    Same author

    A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults.

    Beneficial microbes·2025

    Iron chelation therapy with desferrioxamine (DFO) in children with thalassemia major shows delayed effectiveness. Continuous subcutaneous DFO requires over a year to reduce iron overload, unlike intramuscular DFO which shows increasing ferritin levels.

    Area of Science:

    • Pediatrics
    • Hematology
    • Pharmacology

    Background:

    • Thalassemia major necessitates regular blood transfusions, leading to iron overload.
    • Iron overload poses significant health risks in patients with thalassemia major.
    • Desferrioxamine (DFO) is a primary iron chelation therapy.

    Purpose of the Study:

    • To evaluate the time-dependent efficacy of desferrioxamine (DFO) in reducing serum ferritin levels in children with thalassemia major.
    • To compare the effectiveness of intramuscular DFO versus continuous subcutaneous DFO infusion.

    Main Methods:

    • A longitudinal study tracking serum ferritin concentrations in two groups of children with thalassemia major.
    • Group 1: 19 children treated with intramuscular DFO (20 mg/kg/day for 20 days/month).

    Related Experiment Videos

  • Group 2: 12 children treated with continuous subcutaneous DFO (≥20 mg/kg/day for 6 days/week).

    • Main Results:

    • Intramuscular DFO showed a progressive increase in serum ferritin over 739 days (8.53 ng/ml/day).
    • Continuous subcutaneous DFO resulted in a lower daily ferritin increase (4.77 ng/ml/day).
    • Serum ferritin levels decreased only after 360 days of subcutaneous DFO treatment, despite ongoing iron contribution from transfusions.

    Conclusions:

    • Continuous subcutaneous DFO demonstrates a delayed but eventual reduction in iron overload.
    • More than one year of subcutaneous DFO treatment is needed to achieve a decrease in body iron stores.
    • Treatment modality and duration significantly impact the effectiveness of iron chelation therapy in thalassemia major.